Program
AXL/FLT3/VEGFR2 Inhibitor KC1036
Its studies are mostly in Esophageal Squamous Cell Carcinoma · Thymus Neoplasms · Sarcoma, Ewing, led by Beijing Konruns Pharmaceutical.
Drug pageAXL/FLT3/VEGFR2 Inhibitor KC1036: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Dec 22, 20237 company-led studies, 6 open or runningNext primary completion: Dec 30, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Konruns Pharmaceutical | 76 open or running | phase 3since Dec 22, 2023 | May 11, 2020 | Dec 30, 2026phase 3 · NCT06194734 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 11, 2020First study: phase 1 study in Advanced Solid TumorsFirst studyNCT04387916 · 207 planned · China
- Jan 27, 2022Phase 2 study in Digestive System TumorsNCT05260385 · 133 planned · China
- Feb 16, 2022No phase study in Healthy SubjectsNCT05265338 · 12 enrolled · China
- Jan 5, 2023Phase 2 study in Thymus NeoplasmsNCT05683886 · 30 planned · China
- Dec 22, 2023Phase 3 study in Esophageal Squamous Cell CarcinomaNCT06194734 · 490 planned · China
- Aug 19, 2024Phase 2 study in Sarcoma, EwingNCT06564272 · 30 planned · China
- Mar 14, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaNCT07481058 · 60 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaNCT06194734
- Apr 1, 2027Primary completion: phase 2 study in Sarcoma, EwingNCT06564272
- Dec 2027Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaNCT07481058
TargetBeta
“An orally bioavailable inhibitor of three receptor tyrosine kinases: AXL (UFO), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2), and the vascular endothelial growth factor receptor type 2 (VEGFR2), ”NCIt, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07481058Esophageal Squamous Cell Carcinoma · China | 2 | Recruiting | Dec 2027 | 60 |
| NCT06564272Sarcoma, Ewing · China | 2 | Recruiting | Apr 1, 2027 | 30 |
| NCT06194734Esophageal Squamous Cell Carcinoma · China | 3 | Recruiting | Dec 30, 2026 | 490 |
| NCT05683886Thymus Neoplasms · China | 2 | Recruiting | Feb 2025 | 30 |
| NCT05265338Healthy Subjects · China | – | Completed | Mar 23, 2022 | 12 |
| NCT05260385Digestive System Tumors · China | 2 | Recruiting | Oct 30, 2025 | 133 |
| NCT04387916Advanced Solid Tumors · China | 1 | Recruiting | Oct 31, 2025 | 207 |
How it is read
Names in the registry
- “KC1036”, 8 entries
Conditions, from the studies’ own filings
- Esophageal Squamous Cell Carcinoma, 2 studies
- Thymus Neoplasms, 1 study
- Sarcoma, Ewing, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.